Rituximab in Neuromyelitis Optica Spectrum Disorders-Reply: Why Not as First-Line Therapy. Reply

Valentina Damato, Amelia Evoli, Raffaele Iorio

Research output: Contribution to journalLetter

Original languageEnglish
Pages (from-to)482-483
Number of pages2
JournalJAMA Neurology
Volume74
Issue number4
DOIs
Publication statusPublished - Apr 1 2017

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Rituximab in Neuromyelitis Optica Spectrum Disorders-Reply: Why Not as First-Line Therapy. Reply. / Damato, Valentina; Evoli, Amelia; Iorio, Raffaele.

In: JAMA Neurology, Vol. 74, No. 4, 01.04.2017, p. 482-483.

Research output: Contribution to journalLetter

@article{e950e0fcb68b4dd4b159484a576d294a,
title = "Rituximab in Neuromyelitis Optica Spectrum Disorders-Reply: Why Not as First-Line Therapy.: Reply",
author = "Valentina Damato and Amelia Evoli and Raffaele Iorio",
year = "2017",
month = "4",
day = "1",
doi = "10.1001/jamaneurol.2016.5936",
language = "English",
volume = "74",
pages = "482--483",
journal = "JAMA Neurology",
issn = "2168-6149",
publisher = "American Medical Association",
number = "4",

}

TY - JOUR

T1 - Rituximab in Neuromyelitis Optica Spectrum Disorders-Reply: Why Not as First-Line Therapy.

T2 - Reply

AU - Damato, Valentina

AU - Evoli, Amelia

AU - Iorio, Raffaele

PY - 2017/4/1

Y1 - 2017/4/1

UR - http://www.scopus.com/inward/record.url?scp=85017598970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017598970&partnerID=8YFLogxK

U2 - 10.1001/jamaneurol.2016.5936

DO - 10.1001/jamaneurol.2016.5936

M3 - Letter

AN - SCOPUS:85017598970

VL - 74

SP - 482

EP - 483

JO - JAMA Neurology

JF - JAMA Neurology

SN - 2168-6149

IS - 4

ER -